Transforming growth factor-β1 (TGF-β1) is a versatile cytokine. It has context-dependent pro-and anti-cell proliferation functions. Activation of latent TGF-β1 requires release of the growth factor from pro-complexes and is regulated through TGF-β binding proteins. Two types of TGF-β binding partners, latent TGF-β-binding proteins (LTBPs) and leucine-richrepeat-containing protein 32 (LRRC32), have been identified and their expression are cell specific. TGF-β1 also plays important roles in acute myeloid leukemia (AML) cells. However, the expression of LTBPs and LRRC32 are lacking in myeloid lineage cells and the binding protein of TGF-β1 in these cells are unknown. Here we show that a novel leucinerich-repeat-containing protein family member, LRRC33, with high mRNA level in AML cells, to be the binding and regulating protein of TGF-β1 in AML cells. Using two representative cell lines MV4-11 and AML193, we demonstrate that the protein expression of LRRC33 and TGF-β1 are correlated. LRRC33 co-localizes and forms complex with latent TGF-β1 protein on the cell surface and intracellularly in these cells. Similar as in other cell types, the activation of TGF-β1 in MV4-11 and AML193 cells are also integrin dependent. We anticipate our study to be a starting point of more comprehensive research on LRRC33 as novel TGF-β regulating protein and potential non-genomic based drug target for AML and other myeloid malignancy.
Introduction
Transforming growth factor-β1 (TGF-β1) is the primary member of the large transforming growth factor-β (TGF-β) family which have crucial roles in multiple processes including cell proliferation, development, wound healing and immune responses [1, 2] . Abnormality of TGF-β function has been implicated in multiple human diseases, including fibrosis, autoimmune diseases and cancer [3] . TGF-β1 is synthesized and secreted in a latent, inactive complex, which contains dimerized non-covalently associated TGF-β1growth factor domain and a large prodomain, the latency associated peptide (LAP) [4] . Throughout this paper we use pro-TGF-a1111111111 a1111111111 a1111111111 a1111111111 a1111111111
β1 to indicate the furin-cleaved latent TGFβ protein. The pro-TGF-β1 latent protein does not have biological activity, thus the release of active TGF-β1 is a critical step for regulating TGF-β1 function in cell signaling.
The activation of the latent TGF-β1 is orchestrated by its binding proteins [5] . There are several known binding partners of pro-TGF-β1. The latent transforming growth factor β binding proteins (LTBPs) consist of 4 isoforms (LTBP-1, -2, -3, and -4), that forms latent complexes with pro-TGF-β1 by covalently binding to LAP via disulfide bonds [6] [7] [8] . LTBP is important in the assembly, storage, and secretion of TGF-β1 in that it targets pro-TGF-β1 to the extracellular matrix and leads to the release of soluble active TGF-β1 upon integrin dependent signaling pathways [5] . Unlike LTBPs that associate with pro-TGF-β1 in extracellular matrix, another protein, glycoprotein-A repetitions predominant protein (GARP), also known as leucine rich repeat containing protein 32 (LRRC32), is a cell membrane associated protein that binds to LAP and directs pro-TGF-β1 to the cell surface of FOXP3+ regulatory T cells and platelets. The GARP-pro-TGF-β1 complex are stored on the cell surface and the integrin-dependent signaling pathway is also required for the release of active TGF-β1 [9] [10] [11] .
TGF-β1 protein is pleiotropic in regulating all stages of hematopoiesis and it has both proliferative and anti-proliferative effects on different cells specific to cell types and cell differentiation stages [12, 13] . Thus, TGF-β1 and its binding proteins have long been potential targets of therapies for different blood cancers. It has been reported that in multiple human acute myeloid leukemia (AML) cell lines, including OCI-AML1, AML193, and THP-1 cells, there are TGF-β1 expression, and the proliferation and differentiation of these cells are affected by TGF-β1 through autocrine and paracrine pathways [14, 15] . However, the regulation of TGF-β1 activation in myeloid leukemia cells is not clearly understood. Previous studies show that LTBPs are expressed primarily in cell types of mesenchymal origin [16] and LRRC32 is reported to mainly express on endothelium cells, platelets, and Foxp3+ regulatory T cells but not on myeloid cells [17] . Recent studies also demonstrate that the association and regulation of pro-TGF-β1 by LRRC32 (GARP) is responsible for Treg and platelets related immune tolerance of tumor cells in breast cancer and colon cancer [18] [19] [20] . We recently reported that LRRC33, a homologous protein of the pro-TGF-β1 binding protein GARP (LRRC32), is covalently linked to the prodomain of TGF-β1, and highly expressed microglia cells in the central nervous system (CNS) where LRRC33 associates with pro-TGF-b1 and regulates TGF-β1 function [21] . Thus, LRRC33 is the potential binding partner of pro-TGF-β1 in other myeloid cells, including human AML cells. Similar with GARP in Treg and platelets, LRRC33 could also have a regulatory function on TGF-β1 in myeloid malignancies.
In this study, we showed that LRRC33 and pro-TGF-β1 co-localize and form a protein complex through disulfide bonds on the cell surface of two human acute myeloid leukemia cell lines: MV4-11 and AML193. We show that the activation of TGF-β1 in MV4-11 and AML193 cells is α V integrin-dependent and correlated with the expression level of LRRC33. Our results suggest that LRRC33 potentially plays an important role in the regulation of TGF-β1 activation in acute myeloid leukemia cells.
Methods and materials

The mRNA expression of LRRC33 and TGF-β1
The mRNA expression data is obtained by Affymetrix Arrays from Cancer Cell Line Encyclopedia of Broad Institute (Boston, MA). The raw data are analyzed and plotted using Prism 7 Graphpad software.
Cell culture and Phorbol 12-myristate 13-acetate (PMA) stimulation of cells
MV4-11 and AML193 cells were obtained from ATCC and were cultured in Iscove's Modified Dulbecco's Medium (IMDM) (ThermoFisher Scientific, Waltham, MA) supplemented with 10% fetal bovine serum (FBS), 5 mM L-glutamine, 1% nonessential amino acids, and 5mM penicillin/streptomycin. Culture medium for AML193 cells was supplemented with 0.005 mg/ ml insulin and 5 ng/ml GM-CSF (Sigma-Aldrich, St. Louis, MO). Cells were cultured at 37˚C in a humidified 5% CO2 atmosphere. Phorbol 12-myristate 13-acetate (PMA) (Sigma-Aldrich, St. Louis, MO) was dissolved in DMSO at the concentration of 1.6 mM/ml, then diluted to 80 nM in cell culture media and incubated with MV4-11 or AML193 cells for 24 hours for cell stimulation.
Antibodies and other reagents
The following antibodies were used in this study: proTGFβ1 antibody TW7-28G11 for Immunoprecipitation (IP) and TW4-2F8 for flow cytometry [21] , biotinylated anti-LAP1 antibody for Western blot (WB) (BAF246; R&D Systems), polyclonal goat anti-LAP1 antibody (R&D Systems), APC-conjugated anti-proTGFβ1 (R&D Systems), mouse IgG (ThermoFisher Scientific), goat IgG (ThermoFisher Scientific) for flow cytometry and confocal microscopy, Brilliant Blue 515 (BB515)-conjugated goat anti-mouse immunoglobulin G (IgG) (Biolegend), Brilliant violet 421 (BV421)-conjugated goat anti-mouse IgG (Biolegend), Alexa633-conjugated donkey anti-goat IgG (ThermoFisher Scientific) for flow cytometry and confocal microscopy, streptavidin-HRP for WB (GE Healthcare, Piscataway, NJ) and anti-α v integrin mouse mAb 272-17E6 (Sigma-Aldrich) for inhibition of TGF-β1 activation. Monoclonal antibody (clone 1/8.8) to human LRRC33 was described [21] . For flow cytometry assay, anti-LRRC33 Ab was labeled by fluorophore Alexa-488 NHS Ester (ThermoFisher Scientific) as per the manufacturer's instructions. Alexa488 conjugated antibody was purified with extensive dialysis in PBS buffer.
Flow cytometry
PMA stimulated or non-stimulated MV4-11 and AML193 Cells were stained and analyzed as described previously [10] . In brief, cells were resuspended and incubated with primary antibodies or direct conjugated antibodies at 1μg/ml in flow cytometry buffer (PBS with 2% FBS) for 60 min on ice. After washing with flow cytometry buffer cells were incubated with secondary antibodies for 30 min on ice and wash twice and analyzed by FACScanto instrument (BD Biosciences). Cell fixation and permeabilization was carried out using the Fixation/Permeabilization Solution Kit (BD Biosciences). The flow cytometry data was analyzed by Flowjo software.
Confocal microscopy
AML193 and MV4-11 cells (with or without PMA stimulation) were harvested from cell culture and fixed with 4% paraformaldehyde (PFA) on glass slides treated with 0.1 mg/ml Llysine. Fixed cells were treated with permeabilization and blocking solution containing 5% BSA, 2% FBS and 0.03% Triton X-100 (Sigma-Aldrich). Primary and secondary antibodies were diluted in PBS containing 5% BSA and 0.05% Triton X-100. Cells were incubated with the primary antibody (1μg/ml) overnight at 4˚C, washed with PBS, and incubated with the secondary Alexa fluorophore-conjugated antibodies (0.5μg/ml) for 1h at 4˚C while protected from light. Slides were then washed with PBS, stained with DAPI for 5 min in room temperature, and coverslipped in ProLong Gold antifade reagent (Invitrogen) and imaged using Olympus Fluoview FV1000 confocal laser scanning microscope. LRRC33 was stained with anti-LRRC33 Ab and Alexa488-anti-mouse Ab; proTGF-β1 was stained with goat anti-LAP polyclonal Ab and Alexa633-anti-goat Ab. Non-specific mouse and goat IgG are used as primary Abs as controls.
Western Blot (WB) and Immunoprecipitation (IP)
AML193 and MV4-11 cells (with or without PMA stimulation) were lysed with lysis buffer (25mM Tris, 150mM NaCl, 1mM EDTA, 1% NP-40, 5% Glyceral) with proteinase inhibitor cocktail (Roche) on ice for 30 min. The lysate was clarified by centrifugation at 12,000 × g for 5 min at 4˚C and the lysate was applied to SDS-PAGE and analyzed by WB. IP is carried out with clarified cell lysate pre-cleaned by protein G sepharose (GE Healthcare), then the cell lysate was incubated with anti-LRRC33 or control mouse IgG (2μg/ml) overnight at 4˚C on a rotator. Protein G Sepharose was then added and incubated at 4˚C for another 1 h. The Sepharose beads were sedimented and washed three times with IP lysis buffer. The bound proteins were eluted by heating at 95˚C in SDS sample buffer, separated by SDS-PAGE, and immunoblotted with antibody to prodomain. Data shown are representative of at least 3 independent assays.
TGF-β1 bioassay
The TGFβ reporter cell line TMLC was a kind gift of Daniel Rifkin (New York University). The TGF-β1 activation assay was performed as previously described [22] . In brief, AML193 and MV4-11 cells with PMA stimulated for 24h or without stimulation are washed twice with PBS and re-suspended in DMEM medium with 0.1%BSA before co-cultured with TMLC cells. Cells were co-cultured in 96-well plate overnight at 37 C˚with 15,000 TMLC cells in each well and increasing numbers of MV4-11 or AML193 cells in DMEM + 0.1%BSA. For integrin Ab inhibition assay, 15,000 TMLC cells were co-cultured with 50,000 MV4-11 or AML193 cells in the presence of 2.5 μg/ml anti-α v integrin (mouse mAb 272-17E6) or control mouse IgG. After co-culture, the cells were washed, lysed and processed using the Luciferase Assay System (Promega) and analyzed by Microplate Reader (BioTek). Data are presented as the mean and standard deviation of four replicates.
Results
Lrrc33 gene expression is the highest in AML cell lines
By searching on the publicly available database Cancer Cell Line Encyclopedia (CCLE), we identified that lrrc33 mRNA level is the highest in 39 AML cell lines compared to cell lines of other types of cancers ( Fig 1A) . Furthermore, the mRNA level of LRRC33 and TGF-β1 are both high and correlated in the AML cell lines ( Fig 1B) . Based on these data, we used two AML cell lines, MV4-11 and AML193, to investigate LRRC33 interaction with pro-TGFb1.
LRRC33 and pro-TGF-β1 are expressed on the surface of MV4-11 and AML193 cells, and the protein level increases after PMA stimulation
To investigate the location of LRRC33 and pro-TGF-β1 in MV4-11 and AML193 cells, we carried out flow cytometry experiments using LRRC33 and pro-TGF-β1 mAbs. Cell surface staining showed that both LRRC33 and pro-TGF-β1 were expressed on the cell surface of MV4-11 and AML193 cells, and the expression level of both proteins were increased after PMA stimulation for 24 hours (Fig 2A) . PMA is utilized as stimulus of cytokine synthesis in the cancer cell lines. Staining of fixed and permeabilized cells indicated that the total amount of protein expression of LRRC33 and pro-TGF-β1 also increased significantly after PMA stimulation ( Fig 2B) . These results indicated the expression of LRRC33 and pro-TGF-β1 was correlated in both non-stimulated and stimulated cells, and suggested that LRRC33, similar to GARP in Treg cells [9] , is a potential pro-TGF-β1 anchoring protein in the MV4-11 and AML193 cells for TGF-β1 activation.
LRRC33 and pro-TGF-β1 form complex and co-localize on the cell surface in the MV4-11 and AML193 cells
To investigate whether LRRC33 and pro-TGF-β1 are co-expressed in MV4-11 and AML193 cells, flow cytometry with double staining using anti-LRRC33 and anti-pro-TGF-β1 mAbs LRRC33 is pro-TGF-β1 binding ligand in human acute myeloid leukemia cells with fixed and permeabilized cells was performed. LRRC33 was expressed on almost all the cells with or without PMA stimulation, while there are 38.5% of MV4-11 and 74.1% AML193 cells expressing both proteins without PMA stimulation and 84.5% of MV4-11 and 95.1% AML193 cells expressing both proteins after PMA stimulation ( Fig 3A) . These data indicated that there is no sub-group of cells that only express pro-TGF-β1 without LRRC33 and most of the stimulated cells expressed LRRC33 and pro-TGF-β1 at the same time. Further, co-localization of LRRC33 and pro-TGF-β1 was observed through confocal microscopy. Fig 3B shows that after PMA stimulation, LRRC33 co-localized with pro-TGF-β1 on the cell surface forming a ring-shaped pattern and in the plasma outside the nucleus (Fig 3B) . The co-localization is not significant in non-PMA stimulated cells, due to low pro-TGF-β1 protein expression without PMA stimulation (Fig 3A and 3B) . We further investigate if LRRC33 interacts with pro-TGF-β1 to form protein complex using immunoprecipitation (IP) and Western blotting (WB). With or without PMA stimulation, MV4-11 and AML193 cell lysates were blotted with antibody to the TGF-β1 prodomain, or IP with the anti-LRRC33 mAb followed by blotting with anti-pro-TGF-β1 Ab. The WB of cell lysate showed that without PMA stimulation, the expression level of pro-TGF-β1 and protein complex is low in MV4-11 cells, whereas pro-TGF-β1 and protein complex level are higher in AML193 cell, possibly due to different background cytokine activation level in those two cell lines ( Fig 4A) . After PMA stimulation expression of both pro-TGF-β1 and the complex increased in both cells with a more significant increase of pro-TGF-β1 alone ( Fig 4A) . We further indicate the protein complex observed in WB is the LRRC33-pro-TGF-β1complex by IP experiment. The IP with anti-LRRC33 mAb and blotting with anti-pro-TGF-β1 Ab demonstrated the association of LRRC33 with pro-TGF-β1 and an increase of protein complex formation after PMA stimulation ( Fig 4B) . The detection of pro-TGF-β1 band in reducing SDS-PAGE compared to the protein complex band in the nonreducing SDS-PAGE indicated that LRRC33 interacts with pro-TGF-β1 through disulfide links ( Fig 4B) . These results demonstrated that LRCC33 binds and disulfide links to pro-TGF-β1 and provided further evidence of LRRC33 being a pro-TGF-β1 regulating protein.
TGF-β1 activation in MV4-11 and AML193 cells was integrin dependent
We next studied TGF-β1 activation in MV4-11 and AML193 cells with or without PMA stimulation using mink lung TGFβ-reporter cell line (TMLC) system. The α V β6 and α V β8 integrins have been shown to activate TGF-β1 [23, 24] . Our result showed that the level of TGF-β1 activation increased in MV4-11 and AML193 cells after PMA stimulation ( Fig 5A and 5B) , and such activation are inhibited 65% and 30% by α v integrin antibodies in the stimulated MV-4-11 and AML193 cells, respectively, cultured with TMLC cells (Fig 5C) . This result indicated that TGF-β1 activation in MV4-11 and AML193 cells was α V integrin-dependent, similar with other cells expressing LTBP or GARP as pro-TGF-β1 ligand. These results further supported our hypothesis that LRRC33 is a cell surface binding partner of pro-TGF-β1 and potentially regulate the activation of TGF-β1 through α V integrin-dependent mechanism like other pro-TGF-β1 binding proteins.
Discussion
In this study, we demonstrated that a recently identified pro-TGF-β1 binding protein, LRRC33, associated with pro-TGF-β1 in human myeloid leukemia cell lines and played a role in TGFb1 activation in these cells. In two models of human myeloid leukemia cell lines, MV4-11 and AML193, LRRC33 co-localizes and forms protein complex with pro-TGF-β1. Although protein expression of pro-TGF-β1 largely relies on activation by PMA, the LRRC33 has high level of background expression without PMA stimulation (Figs 2, 3 and 4) , indicating a potential housekeeping role of LRRC33 in AML cells. We also show that TGF-β1 activation in these two cells lines are partially blocked, with MV-4-11 inhibited more significantly (Fig 5) . Such activation inhibition suggests a similar TGF-β1 activating mechanism by LRRC33 to LTBP and GARP in other cells types. Given that TGF-β1 is a latent protein relying on its binding partners and integrin for activation, our data suggest LRRC33 is the potential regulating LRRC33 is pro-TGF-β1 binding ligand in human acute myeloid leukemia cells protein of TGF-β1 function in human myeloid leukemia cells. The regulatory role of LRRC33 in AML could be further validated with LRRC33 knock-out cell lines in future studies.
In previous researches, LRRC33 is known as the Negative Regulator of Reactive Oxygen Species (NRROS), and its function is down-regulating of reactive oxygen species during host defense and autoimmunity on gene knock-out mice [25] . And a following research by another group indicates that LRRC33 regulates osteoclast differentiation [26] . In our previous research, LRRC33 is pro-TGF-β1 binding ligand in human acute myeloid leukemia cells it is indicated that the LRRC33 homologous protein, GARP (LRRC32), binds to pro-TGF-β1 and exert TGF-β1 regulating functions [17] . Further, our recent publication demonstrates that LRRC33 is expressed in microglia cells in the CNS and Lrrc33 knockout mice appear to develop CNS vascular abnormalities associated with deficiency in TGF-β activation [21] . LRRC33 is pro-TGF-β1 binding ligand in human acute myeloid leukemia cells These evidences prompt our hypothesis of LRRC33 as a novel binding and regulating protein of TGF-β1 in myeloid lineage cells. Nevertheless, our findings are not necessarily contradictory to the aforementioned studies given that TGF-β1 has been shown to negatively regulate innate immunity pathways [27] and down regulate both secretion of pro-inflammatory cytokines and reactive oxygen species production [28] .
The mRNA array data of LRRC33 and TGF-β1 from CCLE (Fig 1) indicate LRRC33 could play pivotal roles in AMLs in the context of TGF-β signaling pathway. It has been reported that treatment of THP-1, another human myeloid cell derived leukemia, with TGF-β1 reduces the growth rate of cells and promotes the differentiation to macrophage [29] . Another report show that TGF-β1 is able to induce the differentiation of human myelogenous leukemia cell line U-937 into macrophages [30] . In addition, other chemical differentiation factors including PMA and retinoic acid were also indicated to induce cell differentiation of promyelocytic leukemia cells HL-60 into macrophage [15] . TGF-β1, PMA and retinoic acid were suggested to be potential treatment for myeloid cell derived leukemia in these researches. However, in our research we indicate that PMA stimulation of MV4-11 and AML193 cells result in significant increase of the expression level of TGF-β1 and LRRC33. In the microenvironment of multiple malignancies TGF-β1 has immune suppressive function, inhibiting the activation and proliferation of T cell, B cells and natural killer cells [31] [32] [33] , which is also reminiscent of GARP's regulatory function on TGF-β1 in the tumor microenvironment of breast cancer and colon cancer [18, 20] . In addition, acute myeloid leukemia cells exhibit resistance to TGF-β1 growth inhibition effect in the process of tumor progression [14] . Thus, the stimulation of myeloid leukemia cell may cause suppression of immune cell function due to excessive TGF-β1 production. Further, in clinical practice, the complex genomic landscape of AML makes it difficult to develop widely applicable targeted therapy. Taken together, LRRC33 or LRRC33-pro-TGF-β1 complex is a potential myeloid cell specific target to regulate TGF-β1 function in cancer cells and tumor microenvironment for non-genomic based therapy of AML and other myeloid cell malignancy in a broader context. We should also notice that mRNA of lrrc33 are also detected in normal myeloid cells, thus the specificity of any potential therapy should be considered carefully.
